Pfizer, Astellas’ Xtandi grabs key nod in nonmetastatic cancer by Tracy Staton Monday, July 16, 2018 Pfizer and Astellas’ prostate cancer med Xtandi nabbed broader FDA approval, setting it up for a head-to-head fight with J&J’s Erleada.
Xtandi, apalutamide up for head-to-head fight in prostate cancer by Tracy Staton Tuesday, February 6, 2018 Pfizer, Astellas and J&J envision a wide-open field for patients whose prostate cancer hasn't spread. But there's a high-stakes market scrum ahead.
Astellas, Pfizer eye bigger Xtandi market as key trial scores by Tracy Staton Thursday, September 14, 2017 After Johnson & Johnson's Zytiga put up notable prostate cancer data, Astellas and Pfizer needed a win for their medicine Xtandi. Now they have one.
